Helicobacter pylori and extragastric diseases

Goni, Elisabetta; Franceschi, Francesco

doi:10.1111/hel.12340

Cited by 81 publications

(71 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If left untreated, it can cause chronic gastritis, which is associated with various gastrointestinal diseases 2. Various extragastric manifestations of H. pylori have also been reported, including idiopathic thrombocytopenia purpura, vitamin B12 deficiency, and metabolic syndrome 3. Studies have reported H. pylori colonization to be as high as 90% among patients with gastric ulcers or cancer 4,5.…”

Section: Introductionmentioning

confidence: 99%

Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis

Lau¹,

Ward²,

Chamberlain³

2016

IDR

View full text Add to dashboard Cite

IntroductionHelicobacter pylori colonization is present in half of the world’s population and can lead to numerous gastrointestinal diseases if left untreated, including peptic ulcer disease and gastric cancer. Although concurrent triple therapy remains the recommended treatment regimen for H. pylori eradication, its success rate and efficacy have been declining. Recent studies have shown that the addition of probiotics can significantly increase eradication rates by up to 50%. This meta-analysis examines the impact of probiotic supplementation on the efficacy of standard triple therapy in eradicating H. pylori.MethodsA comprehensive literature search was conducted using PubMed, Cochrane Central Registry of Controlled Trials, and Google Scholar (time of inception to 2016) to identify all published randomized control trials (RCTs) assessing the use of probiotics in addition to triple therapy for the treatment of H. pylori. Searches were conducted using the keywords “probiotics”, “triple therapy”, and “Helicobacter pylori”. RCTs comparing the use of probiotics and standard triple therapy with standard triple therapy alone for any duration in patients of any age diagnosed with H. pylori infection were included. H. pylori eradication rates (detected using urea breath test or stool antigen) were analyzed as-per-protocol (APP) and intention-to-treat (ITT).ResultsA total of 30 RCTs involving 4,302 patients APP and 4,515 patients ITT were analyzed. The addition of probiotics significantly increased eradication rates by 12.2% (relative risk [RR] =1.122; 95% confidence interval [CI], 1.091–1.153; P<0.001) APP and 14.1% (RR =1.141; 95% CI, 1.106–1.175; P<0.001) ITT. Probiotics were beneficial among children and adults, as well as Asians and non-Asians. No significant difference was observed in efficacy between the various types of probiotics. The risk of diarrhea, nausea, vomiting, and epigastric pain was also reduced.ConclusionThe addition of probiotics is associated with improved H. pylori eradication rates in both children and adults, as well as Asians and non-Asians. Lactobacillus, Bifidobacterium, Saccharomyces, and mixtures of probiotics appear beneficial in H. pylori eradication. Furthermore, the reduction in antibiotic-associated side effects such as nausea, vomiting, diarrhea, and epigastric pain improves medication tolerance and patient compliance. Given the consequences associated with chronic H. pylori infection, the addition of probiotics to the concurrent triple therapy regimen should be considered in all patients with H. pylori infection. However, further studies are required to identify the optimal probiotic species and dose.

show abstract

Section: Introductionmentioning

confidence: 99%

Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis

Lau¹,

Ward²,

Chamberlain³

2016

IDR

View full text Add to dashboard Cite

show abstract

“…Moreover, cecropins produced by H. pylori inhibit the growth of competing organisms [9], as well as a P-type ATPase, which helps prevent excessive alkalinization of the microenvironment by urease [10]. This last result allowed to hypothesize a role played by H. pylori in other diseases and some evidences has also been pointed out; indeed, this bacterium was shown to survive within monocytes and polymorphonuclear cells, thereby potentially travelling throughout the body [11][12][13].…”

Section: Introductionmentioning

confidence: 95%

Is Sudden Sensori-neural Hearing Loss an Additional Extra Digestive Disease Associated with HP Infection?

Ponzetto¹,

Cavallo²,

Alushi³

et al. 2017

J Clin Gastroenterol Hepatol

View full text Add to dashboard Cite

Background: Sudden Sensori-neural Hearing Loss (SSHL) is an abrupt failure of the cochlear function of unknown etiology. Possible causes include chronic infections leading to increased systemic levels of cytokines, which could damage the cochlear pumps H + , K + -and Na + , K + -ATPases. Helicobacter pylori infection stimulates systemic cytokine production. Proton pumps in cochlea and stomach are almost identical.

show abstract

“…Whereas H. pylori was initially thought only to cause disease in the upper gut, this microorganism has been implicated in several extra-digestive conditions 6 Recently, infection with H. pylori has emerged as a potential risk factor for type 2 diabetes 7,8 . In some observational studies, H. pylori infection has been associated with glucose intolerance or diabetes, but this has not been a consistent finding 9–20 .…”

Section: Introductionmentioning

confidence: 99%

H. pylori seroprevalence and risk of diabetes: An ancillary case–control study nested in the diabetes prevention program

Alzahrani

Nelson

Moss

et al. 2017

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

OBJECTIVE To determine the association between H. pylori infection and risk of incident diabetes in adults at high risk for diabetes who participated in the Diabetes Prevention Program (DPP) study. METHODS In a nested case-control study conducted among 421 adults with newly diagnosed diabetes and 421 matched controls, we examined the association between serological status of H. pylori at baseline and risk of incident diabetes over a mean follow-up period of 2.6 years. Using data from the baseline visit of the DPP, we also examined the cross-sectional association between presence of H. pylori antibodies and insulin sensitivity, insulin secretion and the disposition index-like measure after a 75-gram oral glucose tolerance test (OGTT). RESULTS At baseline, H. pylori antibodies were present in 40% of participants who developed diabetes and 39% of controls. After adjusting for matching factors, there was no association between exposure to H. pylori and incident diabetes (odds ratio [OR] of 1.04 (95% CI, 0.77 to 1.40). In cross-sectional analyses, H. pylori status was not significantly associated with insulin sensitivity and disposition index-like measure from OGTT. CONCLUSIONS In adults at high risk for diabetes, H. pylori seropositivity was not associated with risk of developing diabetes.

show abstract

Helicobacter pylori and extragastric diseases

Cited by 81 publications

References 38 publications

Probiotics improve the efficacy of standard triple therapy in the eradication of <em>Helicobacter pylori</em>: a meta-analysis

Probiotics improve the efficacy of standard triple therapy in the eradication of <em>Helicobacter pylori</em>: a meta-analysis

Is Sudden Sensori-neural Hearing Loss an Additional Extra Digestive Disease Associated with HP Infection?

H. pylori seroprevalence and risk of diabetes: An ancillary case–control study nested in the diabetes prevention program

Contact Info

Product

Resources

About